|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 6:69–90. 2011. View Article : Google Scholar
|
|
2
|
Christensen JG, Zou HY, Arango ME, et al:
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor
of anaplastic lymphoma kinase and c-Met, in experimental models of
anaplastic large-cell lymphoma. Mol Cancer Ther. 6:3314–3322. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zou HY, Li Q, Lee JH, et al: An orally
available small-molecule inhibitor of c-Met, PF-2341066, exhibits
cytoreductive antitumor efficacy through antiproliferative and
antiangiogenic mechanisms. Cancer Res. 67:4408–4417. 2007.
View Article : Google Scholar
|
|
4
|
Timofeevski SL, McTigue MA, Ryan K, et al:
Enzymatic characterization of c-Met receptor tyrosine kinase
oncogenic mutants and kinetic studies with aminopyridine and
triazolopyrazine inhibitors. Biochemistry. 48:5339–5349. 2009.
View Article : Google Scholar
|
|
5
|
Li Y, Ye X, Liu J, et al: Evaluation of
EML4-ALK fusion proteins in non-small cell lung cancer using small
molecule inhibitors. Neoplasia. 13:1–11. 2011.PubMed/NCBI
|
|
6
|
Ou SH, Bazhenova L, Camidge DR, et al:
Rapid and dramatic radiographic and clinical response to an ALK
inhibitor (crizotinib, PF02341066) in an ALK translocation-positive
patient with non-small cell lung cancer. J Thorac Oncol.
5:2044–2046. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Crinò L, Kim D, Riely GJ, et al: Initial
phase II results with crizotinib in advanced ALK-positive non-small
cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol.
29:75142011.
|
|
8
|
Kwak EL, Bang YJ, Camidge DR, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Klonisch T, Wiechec E, Hombach-Klonisch S,
et al: Cancer stem cell markers in common cancers - therapeutic
implications. Trends Mol Med. 14:450–460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dingli D and Michor F: Successful therapy
must eradicate cancer stem cells. Stem Cells. 24:2603–2610. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kondo T, Setoguchi T and Taga T:
Persistence of a small subpopulation of cancer stem-like cells in
the C6 glioma cell line. Proc Natl Acad Sci USA. 101:781–786. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu C, Wei Q, Utomo V, et al: Side
population cells isolated from mesenchymal neoplasms have tumor
initiating potential. Cancer Res. 67:8216–8222. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Szotek PP, Pieretti-Vanmarcke R, Masiakos
PT, et al: Ovarian cancer side population defines cells with stem
cell-like characteristics and Mullerian Inhibiting Substance
responsiveness. Proc Natl Acad Sci USA. 103:11154–11159. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krysko DV, Vanden Berghe T, D’Herde K, et
al: Apoptosis and necrosis: detection, discrimination and
phagocytosis. Methods. 44:205–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alessandri G, Filippeschi S, Sinibaldi P,
et al: Influence of gangliosides on primary and metastatic
neoplastic growth in human and murine cells. Cancer Res.
47:4243–4247. 1987.PubMed/NCBI
|
|
16
|
Ivković-Kapicl T, Knelević-Usaj S,
Panjković M, et al: Immunohistochemical analysis of angiogenesis in
invasive ductal breast carcinoma with correlations to
clinicopathological factor. Vojnosanit Pregl. 63:635–642. 2006.(In
Serbian).
|
|
17
|
Qin BY, Lam SS, Correia JJ, et al: Smad3
allostery links TGF-β receptor kinase activation to transcriptional
control. Genes Dev. 16:1950–1963. 2002.PubMed/NCBI
|
|
18
|
Martínez T and Pascual A: Gene expression
profile in β-amyloid-treated SH-SY5Y neuroblastoma cells. Brain Res
Bull. 72:225–231. 2007.
|
|
19
|
Zillhardt M, Christensen JG and Lengyel E:
An orally available small-molecule inhibitor of c-Met, PF-2341066,
reduces tumor burden and metastasis in a preclinical model of
ovarian cancer metastasis. Neoplasia. 12:1–10. 2010.
|
|
20
|
Tumati V, Kumar S, Yu L, et al: Effect of
PF-02341066 and radiation on non-small cell lung cancer cells.
Oncol Rep. 29:1094–1100. 2012.PubMed/NCBI
|
|
21
|
Hirschmann-Jax C, Foster AE, Wulf GG, et
al: A distinct ‘side population’ of cells with high drug efflux
capacity in human tumor cells. Proc Natl Acad Sci USA.
101:14228–14233. 2004.
|
|
22
|
Bronte G, Rizzo S, La Paglia L, et al:
Driver mutations and differential sensitivity to targeted
therapies: a new approach to the treatment of lung adenocarcinoma.
Cancer Treat Rev. 36(Suppl 3): S21–S29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garber K: ALK, lung cancer, and
personalized therapy: portent of the future? J Natl Cancer Inst.
102:672–675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Janku F, Stewart DJ and Kurzrock R:
Targeted therapy in non-small-cell lung cancer - is it becoming a
reality? Nat Rev Clin Oncol. 7:401–414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Challen GA and Little MH: A side order of
stem cells: the SP phenotype. Stem Cells. 24:3–12. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hadnagy A, Gaboury L, Beaulieu R, et al:
SP analysis may be used to identify cancer stem cell populations.
Exp Cell Res. 312:3701–3710. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shaw AT, Yeap BY, Mino-Kenudson M, et al:
Clinical features and outcome of patients with non-small-cell lung
cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia P, Mou FF and Wang LW: Predictive role
of computer simulation in assessing signaling pathways of
crizotinib-treated A549 lung cancer cells. Asian Pac J Cancer Prev.
13:3119–3121. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jacob D, Davis J, Zhu H, et al:
Suppressing orthotopic pancreatic tumor growth with a
fiber-modified adenovector expressing the TRAIL gene from the human
telomerase reverse transcriptase promoter. Clin Cancer Res.
10:3535–3541. 2004. View Article : Google Scholar
|
|
30
|
Zhu H, Zhang L, Huang X, et al: Overcoming
acquired resistance to TRAIL by chemotherapeutic agents and calpain
inhibitor I through distinct mechanisms. Mol Ther. 9:666–673. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grau AM, Zhang L, Wang W, et al: Induction
of p21waf1 expression and growth inhibition by transforming growth
factor β involve the tumor suppressor gene DPC4 in human pancreatic
adenocarcinoma cells. Cancer Res. 57:3929–3934. 1997.
|
|
32
|
Guo Y and Kyprianou N: Overexpression of
transforming growth factor (TGF) β1 type II receptor restores
TGF-β1 sensitivity and signaling in human prostate cancer cells.
Cell Growth Differ. 9:185–193. 1998.
|
|
33
|
Tang MR, Wang YX, Guo S, et al: CSMD1
exhibits antitumor activity in A375 melanoma cells through
activation of the Smad pathway. Apoptosis. 17:927–937. 2012.
View Article : Google Scholar : PubMed/NCBI
|
